, TESTBANK FOR Advanced Pharmacology for
Prescribers Luu
Notes
1- The file is chapter after chapter.
2- We have shown you few pages sample.
3- The file contains all Appendix and Excel sheet
if it exists.
4- We have all what you need, we make update
at every time. There are many new editions
waiting you.
5- If you think you purchased the wrong file You
can contact us at every time, we can replace it
with true one.
Our email:
, Test Bank for
ADVANCED PHARMACOLOGY
FOR PRESCRIBERS
BRENT LUU, PHARMD, BCPS, BCACP
GERALD KAYINGO, PHD, MMSc, PA-C
VIRGINIA MCCOY HASS, DNP, MSN,
RN,
FNP-C, PA-Cr
ISBN: 978-0-8261-9616-3
,Copyright © 2021 Springer Publishing Company, LLC
All rights reserved.
This work is protected by U.S. copyright laws and is provided solely for the use of instructors in teaching
their courses and as an aid for student learning. No part of this publication may be sold, reproduced,
stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical,
photocopying, recording, or otherwise, without the prior permission of Springer Publishing Company,
LLC.
Springer Publishing Company, LLC
11 West 42nd Street
New York, NY 10036
www.springerpub.com
ISBN: 978-0-8261-9616-3
The author and the publisher of this Work have made every effort to use sources believed to be reliable to
provide information that is accurate and compatible with the standards generally accepted at the time of
publication. The author and publisher shall not be liable for any special, consequential, or exemplary
damages resulting, in whole or in part, from the readers’ use of, or reliance on, the information contained
in this book. The publisher has no responsibility for the persistence or accuracy of URLs for external or
third-party Internet websites referred to in this publication and does not guarantee that any content on
such websites is, or will remain, accurate or appropriate.
, PART I
FOUNDATIONS OF PHARMACOLOGY
AND PRESCRIBING
© Springer Publishing Group, LLC 1
,Chapter 1: An Introduction to Evidence-Based Clinical Practice
Guidelines
Adebola Olarewaju and George W. Rodway
Multiple Choice Questions
1. The Institute of Medicine (IOM) report on quality and the health system for the 21st century focused
on:
A. Reducing the cost of care
B. Improving the speed of care
*C. Closing the gap between optimal healthcare delivery and actual clinical care
D. Guiding the direction of medical and pharmaceutical research for current and future clinicians
Answer: Correct answer is option (C).
2. Clinical practice guidelines improve outcomes of clinical care by:
A. Providing prognostic information
B. Mandating steps to be taken in the care of the patient
*C. Applying rigorously designed studies to everyday care
D. Listing the proven diagnostic and therapeutic agents that should be used for relevant patients
Answer: Correct answer is option (C).
3. Which of the following is likely to be useful as a basis for clinical practice guidelines?
*A. Several large randomized controlled clinical trials
B. A review of a single study from a highly reputable journal
C. The teachings of a senior professor of medicine from a highly reputable journal
D. A clinician’s personal experience with similar patients with similar conditions
Answer: Correct answer is option (A).
4. Clinical practice guidelines are written primarily to:
*A. Assist clinician and patient decisions about appropriate healthcare for specific clinical
circumstances
B. Guide insurance companies on which tests and treatments to pay for
C. Set legal standards of care for a particular disease
D. Tell patients which medical centers to go to for testing
Answer: Correct answer is option (A).
5. What variables limit the usefulness of published clinical practice guidelines?
*A. Bias
B. Conciseness
C. Recommendations for accessible tests
D. Recommendations for affordable treatments
Answer: Correct answer is option (A).
2 © Springer Publishing Group, LLC
,6. A clinician is evaluating a patient for a long history of bitemporal headaches. The patient explains
that she heard on television that she should have an MRI, based on a study from Harvard. What is the
next step that the clinicians should take?
A. Order an MRI
B. Refer the patient to a specialist
C. Look up the study to which the patient is referring and evaluate its scientific and statistical
validity
*D. Look up the most recent clinical practice guidelines from the related specialty society and share
those with her
Answer: Correct answer is option (D).
7. Recommendations in clinical practice guidelines should be evaluated based on:
*A. The effective size of the main outcomes
B. The author’s affiliated institution
C. The journal in which it is published
D. What other experts say about the recommendations
Answer: Correct answer is option (A).
8. Advantages of following a well-designed clinical practice guideline include:
A. The patient will receive the least expensive evaluation and treatment protocol
B. The patient’s insurance is more likely to cover the cost of care
*C. The patient will receive care that is supported by research and evidence
D. The doctor cannot be sued for malpractice
Answer: Correct answer is option (C).
9. One of the crucial factors to consider when creating a guideline, including:
A. The audience for the guideline
*B. Which evidence to include
C. Which journal to publish in
D. The desires of the financial sponsor of the research
Answer: Correct answer is option (B).
10. The Strength of Recommendation rating in a clinical practice guideline is influenced by:
*A. The balance of risks, burdens, and benefits of an intervention
B. The presence of a statement in each study regarding conflict of interest and ethics approval
C. The age group of the patients
D. The frequency of the disease
Answer: Correct answer is option (A).
© Springer Publishing Group, LLC 3
,Chapter 2: Pharmacokinetics
Patrick Chan and James Uchizono
Multiple Choice Questions
1. Which of the following statements best describes pharmacokinetics?
*A. It is what the body does to the drug
B. It is what the drug does to the body
C. It is the therapeutic monitoring of the drug
D. It is how a disease affects a drug
Answer: Correct answer is option (A).
2. An essential hypothesis of pharmacokinetics is:
A. The dose must correlate with the pharmacological effect
B. Adverse reactions must correlate with plasma concentrations
C. There is a qualitative relationship between dose and pharmacological effect
*D. There is a quantitative relationship between drug concentration and pharmacological effect
Answer: Correct answer is option (D).
3. A therapeutic drug monitoring protocol would include which of the following factors?
A. Ethnicity
B. Socioeconomic status
*C. Defined therapeutic endpoints
D. Smoking history
Answer: Correct answer is option (C).
4. Which of the following affects the absorption of a drug?
A. Clearance
*B. Route of delivery
C. Plasma pH
D. Patient body weight
Answer: Correct answer is option (B).
5. Drug interactions involving cytochrome P450 enzymes may:
A. Increase drug concentrations
B. Decrease drug concentrations
C. Increase distribution
*D. A and B
Answer: Correct answer is option (D).
6. Bioavailability is defined as:
A. The amount of drug made available following metabolism
B. The amount of drug present in the plasma following distribution
*C. The extent of drug absorption, or the percentage or fraction of the parent compound that reaches
systemic (plasma) circulation
D. The extent of drug absorption following metabolism and excretion
4 © Springer Publishing Group, LLC
, Answer: Correct answer is option (C).
7. Creatinine clearance is an estimate of:
*A. Glomerular filtration
B. Hepatic metabolism
C. Biliary excretion
D. Pulmonary excretion
Answer: Correct answer is option (A).
8. If a drug has a small value for volume of distribution, Vd, it is most likely residing in the:
A. Brain
*B. Blood
C. Bone
D. Spleen
Answer: Correct answer is option (B).
9. The loading dose for a patient can be calculated using:
*A. Vd and Cptarget
B. Cl and F
C. Vd and Cl
D. Cptarget and F
Answer: Correct answer is option (A).
10. Half-life is useful for estimating:
A. Clearance
B. Volume of distribution
*C. The time to reach steady-state
D. Absorption
Answer: Correct answer is option (C).
© Springer Publishing Group, LLC 5
, Chapter 3: Pharmacodynamics
James Uchizono and Patrick Chan
Multiple Choice Questions
1. Pharmacodynamics may be defined as:
A. The effect of the body on a drug
*B. The effect of a drug on the body
C. The effect of body dynamic posture on drug distribution
D. The same as pharmacokinetics
Answer: Correct answer is option (B).
2. In pharmacodynamics equations, when volume is constant, the concentration (C) of a drug is
analogous to:
*A. Dose
B. Clearance
C. Receptor affinity
D. Renal and hepatic metabolism
Answer: Correct answer is option (A).
3. The pharmacodynamics characteristics of small-molecule drugs include:
A. A linear dose–response curve
B. An effect that does not require receptors
C. A wide therapeutic index
*D. A dose–response curve that is sigmoidal in shape
Answer: Correct answer is option (D).
4. In the Emax equation, the Emax parameter is:
A. The maximum tolerated dose
*B. The maximum limit of the effect in response to the drug
C. The maximum duration of action
D. The maximum concentration of a given dose of a drug
Answer: Correct answer is option (B).
5. Tachyphylaxis, or drug tolerance, to opioids and certain cardio supportive intravenous drugs can be
explained using:
A. A simple sigmoidal dose–response curve
*B. A complex mathematical model requiring differential equations
C. A linear dose–response curve
D. The Emax model
Answer: Correct answer is option (B).
6. The therapeutic index of a drug is:
A. The ratio between the average lethal dose and the average dose that causes side effects
B. The highest level of drug concentration that causes toxicity
6 © Springer Publishing Group, LLC
Prescribers Luu
Notes
1- The file is chapter after chapter.
2- We have shown you few pages sample.
3- The file contains all Appendix and Excel sheet
if it exists.
4- We have all what you need, we make update
at every time. There are many new editions
waiting you.
5- If you think you purchased the wrong file You
can contact us at every time, we can replace it
with true one.
Our email:
, Test Bank for
ADVANCED PHARMACOLOGY
FOR PRESCRIBERS
BRENT LUU, PHARMD, BCPS, BCACP
GERALD KAYINGO, PHD, MMSc, PA-C
VIRGINIA MCCOY HASS, DNP, MSN,
RN,
FNP-C, PA-Cr
ISBN: 978-0-8261-9616-3
,Copyright © 2021 Springer Publishing Company, LLC
All rights reserved.
This work is protected by U.S. copyright laws and is provided solely for the use of instructors in teaching
their courses and as an aid for student learning. No part of this publication may be sold, reproduced,
stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical,
photocopying, recording, or otherwise, without the prior permission of Springer Publishing Company,
LLC.
Springer Publishing Company, LLC
11 West 42nd Street
New York, NY 10036
www.springerpub.com
ISBN: 978-0-8261-9616-3
The author and the publisher of this Work have made every effort to use sources believed to be reliable to
provide information that is accurate and compatible with the standards generally accepted at the time of
publication. The author and publisher shall not be liable for any special, consequential, or exemplary
damages resulting, in whole or in part, from the readers’ use of, or reliance on, the information contained
in this book. The publisher has no responsibility for the persistence or accuracy of URLs for external or
third-party Internet websites referred to in this publication and does not guarantee that any content on
such websites is, or will remain, accurate or appropriate.
, PART I
FOUNDATIONS OF PHARMACOLOGY
AND PRESCRIBING
© Springer Publishing Group, LLC 1
,Chapter 1: An Introduction to Evidence-Based Clinical Practice
Guidelines
Adebola Olarewaju and George W. Rodway
Multiple Choice Questions
1. The Institute of Medicine (IOM) report on quality and the health system for the 21st century focused
on:
A. Reducing the cost of care
B. Improving the speed of care
*C. Closing the gap between optimal healthcare delivery and actual clinical care
D. Guiding the direction of medical and pharmaceutical research for current and future clinicians
Answer: Correct answer is option (C).
2. Clinical practice guidelines improve outcomes of clinical care by:
A. Providing prognostic information
B. Mandating steps to be taken in the care of the patient
*C. Applying rigorously designed studies to everyday care
D. Listing the proven diagnostic and therapeutic agents that should be used for relevant patients
Answer: Correct answer is option (C).
3. Which of the following is likely to be useful as a basis for clinical practice guidelines?
*A. Several large randomized controlled clinical trials
B. A review of a single study from a highly reputable journal
C. The teachings of a senior professor of medicine from a highly reputable journal
D. A clinician’s personal experience with similar patients with similar conditions
Answer: Correct answer is option (A).
4. Clinical practice guidelines are written primarily to:
*A. Assist clinician and patient decisions about appropriate healthcare for specific clinical
circumstances
B. Guide insurance companies on which tests and treatments to pay for
C. Set legal standards of care for a particular disease
D. Tell patients which medical centers to go to for testing
Answer: Correct answer is option (A).
5. What variables limit the usefulness of published clinical practice guidelines?
*A. Bias
B. Conciseness
C. Recommendations for accessible tests
D. Recommendations for affordable treatments
Answer: Correct answer is option (A).
2 © Springer Publishing Group, LLC
,6. A clinician is evaluating a patient for a long history of bitemporal headaches. The patient explains
that she heard on television that she should have an MRI, based on a study from Harvard. What is the
next step that the clinicians should take?
A. Order an MRI
B. Refer the patient to a specialist
C. Look up the study to which the patient is referring and evaluate its scientific and statistical
validity
*D. Look up the most recent clinical practice guidelines from the related specialty society and share
those with her
Answer: Correct answer is option (D).
7. Recommendations in clinical practice guidelines should be evaluated based on:
*A. The effective size of the main outcomes
B. The author’s affiliated institution
C. The journal in which it is published
D. What other experts say about the recommendations
Answer: Correct answer is option (A).
8. Advantages of following a well-designed clinical practice guideline include:
A. The patient will receive the least expensive evaluation and treatment protocol
B. The patient’s insurance is more likely to cover the cost of care
*C. The patient will receive care that is supported by research and evidence
D. The doctor cannot be sued for malpractice
Answer: Correct answer is option (C).
9. One of the crucial factors to consider when creating a guideline, including:
A. The audience for the guideline
*B. Which evidence to include
C. Which journal to publish in
D. The desires of the financial sponsor of the research
Answer: Correct answer is option (B).
10. The Strength of Recommendation rating in a clinical practice guideline is influenced by:
*A. The balance of risks, burdens, and benefits of an intervention
B. The presence of a statement in each study regarding conflict of interest and ethics approval
C. The age group of the patients
D. The frequency of the disease
Answer: Correct answer is option (A).
© Springer Publishing Group, LLC 3
,Chapter 2: Pharmacokinetics
Patrick Chan and James Uchizono
Multiple Choice Questions
1. Which of the following statements best describes pharmacokinetics?
*A. It is what the body does to the drug
B. It is what the drug does to the body
C. It is the therapeutic monitoring of the drug
D. It is how a disease affects a drug
Answer: Correct answer is option (A).
2. An essential hypothesis of pharmacokinetics is:
A. The dose must correlate with the pharmacological effect
B. Adverse reactions must correlate with plasma concentrations
C. There is a qualitative relationship between dose and pharmacological effect
*D. There is a quantitative relationship between drug concentration and pharmacological effect
Answer: Correct answer is option (D).
3. A therapeutic drug monitoring protocol would include which of the following factors?
A. Ethnicity
B. Socioeconomic status
*C. Defined therapeutic endpoints
D. Smoking history
Answer: Correct answer is option (C).
4. Which of the following affects the absorption of a drug?
A. Clearance
*B. Route of delivery
C. Plasma pH
D. Patient body weight
Answer: Correct answer is option (B).
5. Drug interactions involving cytochrome P450 enzymes may:
A. Increase drug concentrations
B. Decrease drug concentrations
C. Increase distribution
*D. A and B
Answer: Correct answer is option (D).
6. Bioavailability is defined as:
A. The amount of drug made available following metabolism
B. The amount of drug present in the plasma following distribution
*C. The extent of drug absorption, or the percentage or fraction of the parent compound that reaches
systemic (plasma) circulation
D. The extent of drug absorption following metabolism and excretion
4 © Springer Publishing Group, LLC
, Answer: Correct answer is option (C).
7. Creatinine clearance is an estimate of:
*A. Glomerular filtration
B. Hepatic metabolism
C. Biliary excretion
D. Pulmonary excretion
Answer: Correct answer is option (A).
8. If a drug has a small value for volume of distribution, Vd, it is most likely residing in the:
A. Brain
*B. Blood
C. Bone
D. Spleen
Answer: Correct answer is option (B).
9. The loading dose for a patient can be calculated using:
*A. Vd and Cptarget
B. Cl and F
C. Vd and Cl
D. Cptarget and F
Answer: Correct answer is option (A).
10. Half-life is useful for estimating:
A. Clearance
B. Volume of distribution
*C. The time to reach steady-state
D. Absorption
Answer: Correct answer is option (C).
© Springer Publishing Group, LLC 5
, Chapter 3: Pharmacodynamics
James Uchizono and Patrick Chan
Multiple Choice Questions
1. Pharmacodynamics may be defined as:
A. The effect of the body on a drug
*B. The effect of a drug on the body
C. The effect of body dynamic posture on drug distribution
D. The same as pharmacokinetics
Answer: Correct answer is option (B).
2. In pharmacodynamics equations, when volume is constant, the concentration (C) of a drug is
analogous to:
*A. Dose
B. Clearance
C. Receptor affinity
D. Renal and hepatic metabolism
Answer: Correct answer is option (A).
3. The pharmacodynamics characteristics of small-molecule drugs include:
A. A linear dose–response curve
B. An effect that does not require receptors
C. A wide therapeutic index
*D. A dose–response curve that is sigmoidal in shape
Answer: Correct answer is option (D).
4. In the Emax equation, the Emax parameter is:
A. The maximum tolerated dose
*B. The maximum limit of the effect in response to the drug
C. The maximum duration of action
D. The maximum concentration of a given dose of a drug
Answer: Correct answer is option (B).
5. Tachyphylaxis, or drug tolerance, to opioids and certain cardio supportive intravenous drugs can be
explained using:
A. A simple sigmoidal dose–response curve
*B. A complex mathematical model requiring differential equations
C. A linear dose–response curve
D. The Emax model
Answer: Correct answer is option (B).
6. The therapeutic index of a drug is:
A. The ratio between the average lethal dose and the average dose that causes side effects
B. The highest level of drug concentration that causes toxicity
6 © Springer Publishing Group, LLC
